ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
$47.9M 137,083 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. reported $48,075,723.50 across General Payments, Research, and Ownership to 94,811 physicians and teaching hospitals across 106,116 transactions.
- $48.1M Top 10% payer
- All-tracks total
- 106,116 Top 10% volume
- Transactions
- 94,811 Top 10% reach
- Recipients
- −$1.7M
- General Payments vs PY2023
Sumitomo Pharma America, Inc. reported $48,075,723.50 across all CMS Open Payments tracks (General + Research + Ownership) to 94,811 physicians and teaching hospitals in Program Year 2024 - ranking #49 of 1,925 reporting manufacturers (0.3% of the all-tracks industry total); General Payments alone were $3,805,644.96, averaging $507.07 per recipient.
How Sumitomo Pharma America, Inc.'s $48.1M all-tracks total breaks down
Sumitomo Pharma America, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
A
94/100
Total payments
A
100/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
C
77/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer sumitomo-pharma-america-inc Sumitomo Pharma America, Inc.
$48.1M · #49/1,925 · 0.3% industry · PY2024
- TOT $48.1M
- RANK #49
- SHARE 0.3%
- TXN 106,116
- RCP 94,811
- CAT 6
- GEN $3.8M
- ΔGEN −$1.7M
- TOP1 3.2%
- PY 2024
Volume peers
Nearest volume peer: ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) ($47.9M)
Sumitomo Pharma America, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Sumitomo Pharma America, Inc.'s CMS-reported General Payments decreased by $1.7M (−30.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: SUMITOMO PHARMA AMERICA, INC.PY2024: Sumitomo Pharma America, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $5,478,809.67
- PY2024
- $3,805,644.96
What the Data Shows for Sumitomo Pharma America, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Sumitomo Pharma America, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Food and Beverage" leads the 6-category general-payment breakdown below at $1.9M (49.1% of General Payments, 93,174 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Sumitomo Pharma America, Inc. made 6 types of general payments. "Food and Beverage" is the largest category at $1.9M, 49.1% of General Payments.
Sumitomo Pharma America, Inc. reports 6 general-payment categories - the top three are Food and Beverage (49.1%), Consulting Fee (23.5%), and Compensation for Services Other Than Consulting (19.7%). The remaining 3 categories make up 7.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Sumitomo Pharma America, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $1.9M | 93,174 | 49.1% |
| Consulting Fee | $892.8K | 275 | 23.5% |
| Compensation for Services Other Than Consulting | $750.5K | 1,031 | 19.7% |
| Grant | $216.0K | 43 | 5.7% |
| Travel and Lodging | $75.3K | 173 | 2.0% |
| Education | $2.4K | 115 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $417,497.85 (11.0%) of $3,805,644.96 in this company's General Payments records across 31,102 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Sumitomo Pharma America, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
William White
$119,915.00 across 11 reported transactions
- 2
The Childrens Hospital of Philadelp
$99,360.00 across 11 reported transactions
- 3
Matt Rosenberg
$75,097.66 across 67 reported transactions
- 4
David Staskin
$65,628.72 across 43 reported transactions
- 5
Aviva Asnis-Alibozek
$57,496.47 across 11 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Sumitomo Pharma America, Inc. ranks #49 of 1,925 by total payments (top 3% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,769 of 1,838 by HHI (bottom 4% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Electronic Waveform Lab, Inc. : $32.0K total payments, HHI 47
- Avvisto Therapeutics, LLC : $8.9K total payments, HHI 47
- Neurocrine Biosciences, Inc. : $14.2M total payments, HHI 47
- W. L. Gore & Associates, Inc. : $5.4M total payments, HHI 47
- Aucta Pharmaceuticals, Inc. : $25.2K total payments, HHI 46
- Axsome Therapeutics, Inc. : $12.2M total payments, HHI 45
- Sumitomo Pharma America, Inc. (this company) : $3.8M total payments, HHI 45
- Phathom Pharmaceuticals, Inc. : $10.7M total payments, HHI 45
- Sun Pharmaceutical Industries Inc. : $6.3M total payments, HHI 45
- Penumbra, Inc. : $5.8M total payments, HHI 45
- Boston Scientific Corporation : $61.8M total payments, HHI 45
- ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) : $3.8M total payments, HHI 44
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Sumitomo Pharma America, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Sumitomo Pharma America, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Sumitomo Pharma America, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Cleerly, Inc.
$47.5M 910 recipients
Compare payment profiles
Scientia Vascular
$46.9M 191 recipients
Compare payment profiles
Novo Nordisk AS
$49.2M 804 recipients
Compare payment profiles
Vektor Medical Inc.
$49.6M 56 recipients
Compare payment profiles
Smith+Nephew, Inc.
$50.5M 71,450 recipients
Compare payment profiles
Put this to use
Sumitomo Pharma America, Inc. ranks #49 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See where Sumitomo Pharma America, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Sumitomo Pharma America, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.